How Pre-mRNA Folding Affects Antisense Oligonucleotide Therapy for Dystrophin Exon Skipping
Author Information
Author(s): Wee Keng Boon, Pramono Zacharias Aloysius Dwi, Wang Jian Li, MacDorman Karl F., Lai Poh San, Yee Woon Chee
Primary Institution: National Neuroscience Institute, Singapore
Hypothesis
The dynamic localization of accessible sites during pre-mRNA transcription affects the design of effective antisense oligonucleotides (AONs) for exon skipping.
Conclusion
The study shows that co-transcriptional pre-mRNA folding significantly influences the accessibility of AON target sites, impacting their efficacy in inducing exon skipping.
Supporting Evidence
- The study demonstrated that the frequency of engaged nucleotides correlates with AON efficacy.
- Engaged nucleotides at the ends of target sites significantly reduce AON performance.
- Longer AONs are less affected by engaged nucleotides compared to shorter AONs.
- Co-transcriptional folding leads to dynamic changes in RNA structure that impact AON accessibility.
Takeaway
This study found that how RNA folds while it's being made can change how well certain medicines work to skip parts of the RNA that cause diseases.
Methodology
The study used a novel scoring methodology to analyze the co-transcriptional binding accessibility of AON target sites based on predicted secondary structures.
Potential Biases
Potential bias in the selection of AONs from different studies may affect the generalizability of the results.
Limitations
The study's findings may not apply to all AONs or other genetic diseases, as it focused specifically on dystrophin exon skipping.
Participant Demographics
The study analyzed AONs targeting dystrophin in human and animal models.
Statistical Information
P-Value
0.0044
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website